Aurobindo Pharma share price hits 52-week high on better Q4 numbers; Credit Suisse gives target of Rs 665

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Aurobindo Pharma share price touched a 52-week high of Rs 780, rising 4 percent in early trade on June 4 after the company reported better numbers for the quarter ended March 2020.

The company's consolidated net profit after JV share and minority interest was up by 45.2 percent to Rs 849.8 crore for the quarter ended March 31, 2020, against Rs 585.4 crore during the same quarter in FY19.

The consolidated revenue from operations grew by 16.4 percent to Rs 6,158.4 crore during the quarter under discussion against Rs 5292.2 crore in the last quarter of FY 19.

Research house Credit Suisse has maintained a neutral call on the stock with target price at Rs 665 per share.

According to the research house, the headline numbers are a beat, along with a good net debt reduction.

The injectable sales were quite weak in the US, down 23 percent QoQ, while it is a beat on strong gross margins and ex-US sales.

However, the sharp increase in expenses offset the benefit from gross margin. The R&D was low in FY20 but should increase in FY21, it added.

In the latest development, United States Food and Drug Administration (US FDA) issued ‘Form 483’ with 9 observations to the company's wholly owned step-down subsidiary AuroLife Pharma LLC’s oral solid manufacturing facility situated at Dayton, New Jersey.

The inspection was carried out between January 13 to February 12, 2020.

We have received a letter from USFDA classifying the inspection as Official Action Indicated (OAI), comapny said in the release.

The company believes that this OAI classification may not have any material impact on the existing revenues, the supplies of its US business or pipeline products at this juncture.

The exclusive sales from this facility is around 2 percent of the group.

At 09:19 hrs, Aurobindo Pharma was quoting at Rs 773.75, up Rs 23.10, or 3.08 percent on the BSE.